Switch theme
Sign up to access all valuation multiples
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded and non-branded, in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the revenue for the company is generated from its injectables segment under which it supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue generating market followed by Middle East and North Africa, United Kingdom, Europe and the rest of the world.
2005
9.5K+
LTM Revenue $2.5B
LTM EBITDA $646M
$7.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Hikma Pharmaceuticals has a last 12-month revenue (LTM) of $2.5B and a last 12-month EBITDA of $646M.
In the most recent fiscal year, Hikma Pharmaceuticals achieved revenue of $4.2B and an EBITDA of $976M.
Hikma Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Hikma Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.5B | XXX | $4.2B | XXX | XXX | XXX |
| Gross Profit | $1.2B | XXX | $1.9B | XXX | XXX | XXX |
| Gross Margin | 47% | XXX | 45% | XXX | XXX | XXX |
| EBITDA | $646M | XXX | $976M | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 23% | XXX | XXX | XXX |
| EBIT | $559M | XXX | $822M | XXX | XXX | XXX |
| EBIT Margin | 23% | XXX | 20% | XXX | XXX | XXX |
| Net Profit | $300M | XXX | $482M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 11% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $1.4B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Hikma Pharmaceuticals's stock price is GBP 21 (or $29).
Hikma Pharmaceuticals has current market cap of GBP 4.7B (or $6.3B), and EV of GBP 5.5B (or $7.4B).
See Hikma Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7.4B | $6.3B | XXX | XXX | XXX | XXX | $2.32 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Hikma Pharmaceuticals has market cap of $6.3B and EV of $7.4B.
Hikma Pharmaceuticals's trades at 1.8x EV/Revenue multiple, and 7.6x EV/EBITDA.
Equity research analysts estimate Hikma Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Hikma Pharmaceuticals has a P/E ratio of 15.7x.
See valuation multiples for Hikma Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6.3B | XXX | $6.3B | XXX | XXX | XXX |
| EV (current) | $7.4B | XXX | $7.4B | XXX | XXX | XXX |
| EV/Revenue | 2.2x | XXX | 1.8x | XXX | XXX | XXX |
| EV/EBITDA | 8.5x | XXX | 7.6x | XXX | XXX | XXX |
| EV/EBIT | 9.9x | XXX | 9.0x | XXX | XXX | XXX |
| EV/Gross Profit | 4.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 15.7x | XXX | 13.1x | XXX | XXX | XXX |
| EV/FCF | 19.4x | XXX | 16.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHikma Pharmaceuticals's last 12 month revenue growth is 1%
Hikma Pharmaceuticals's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Hikma Pharmaceuticals's rule of 40 is 20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Hikma Pharmaceuticals's rule of X is 29% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Hikma Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1% | XXX | -9% | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 4% | XXX | 9% | XXX | XXX | XXX |
| Rule of 40 | 20% | XXX | 24% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 29% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 26% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hikma Pharmaceuticals acquired XXX companies to date.
Last acquisition by Hikma Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Hikma Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Hikma Pharmaceuticals founded? | Hikma Pharmaceuticals was founded in 2005. |
| Where is Hikma Pharmaceuticals headquartered? | Hikma Pharmaceuticals is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| How many employees does Hikma Pharmaceuticals have? | As of today, Hikma Pharmaceuticals has 9.5K+ employees. |
| Who is the CEO of Hikma Pharmaceuticals? | Hikma Pharmaceuticals's CEO is Mr. Riad Mishlawi. |
| Is Hikma Pharmaceuticals publicy listed? | Yes, Hikma Pharmaceuticals is a public company listed on LON. |
| What is the stock symbol of Hikma Pharmaceuticals? | Hikma Pharmaceuticals trades under HIK ticker. |
| When did Hikma Pharmaceuticals go public? | Hikma Pharmaceuticals went public in 2005. |
| Who are competitors of Hikma Pharmaceuticals? | Similar companies to Hikma Pharmaceuticals include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Hikma Pharmaceuticals? | Hikma Pharmaceuticals's current market cap is $6.3B |
| What is the current revenue of Hikma Pharmaceuticals? | Hikma Pharmaceuticals's last 12 months revenue is $2.5B. |
| What is the current revenue growth of Hikma Pharmaceuticals? | Hikma Pharmaceuticals revenue growth (NTM/LTM) is 1%. |
| What is the current EV/Revenue multiple of Hikma Pharmaceuticals? | Current revenue multiple of Hikma Pharmaceuticals is 2.2x. |
| Is Hikma Pharmaceuticals profitable? | Yes, Hikma Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Hikma Pharmaceuticals? | Hikma Pharmaceuticals's last 12 months EBITDA is $646M. |
| What is Hikma Pharmaceuticals's EBITDA margin? | Hikma Pharmaceuticals's last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of Hikma Pharmaceuticals? | Current EBITDA multiple of Hikma Pharmaceuticals is 8.5x. |
| What is the current FCF of Hikma Pharmaceuticals? | Hikma Pharmaceuticals's last 12 months FCF is $284M. |
| What is Hikma Pharmaceuticals's FCF margin? | Hikma Pharmaceuticals's last 12 months FCF margin is 11%. |
| What is the current EV/FCF multiple of Hikma Pharmaceuticals? | Current FCF multiple of Hikma Pharmaceuticals is 19.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
